StockWatch
·
HomeLiveReports
Filing
Q3

LUPIN LTD.

LUPINFY2612 Feb 2026
Revenue+1.7%
Net Profit-20.5%
OPM25.61%

P&L

Quarterly Consolidated

Revenue
+1.7%7.2K
Expenditure
+4.0%5.3K
Net Profit
-20.5%1.2K
NPM 16.21%-22.1%EPS ₹25.74-20.5%

vs Q2 FY26

Lupin Ltd Reports Strong Q3 FY2026 Results with 26.4% YoY Sales Growth

12 Feb 2026 · 12 Feb, 10:53 pm

Summary

Pharma major Lupin Limited reported its financial performance for the quarter ending December 31, 2025. The company's sales grew by 26.4% YoY and EBITDA margin increased by 840 bps YoY.

Key Highlights

  1. 1

    Q3 FY2026 sales: INR 71,005 Mn

  2. 2

    Q3 FY2026 EBITDA: INR 23,766 Mn

  3. 3

    Q3 FY2026 EBITDA margin: 33.5%

  4. 4

    Q3 FY2026 Adjusted PBT: INR 15,220 Mn

  5. 5

    Q3 FY2026 PAT: INR 11,805 Mn

  6. 6

    Gross profit: INR 52,224 Mn

  7. 7

    Gross margin: 73.5%

  8. 8

    Personnel cost: INR 11,433 Mn

  9. 9

    Manufacturing and other expenses: INR 19,366 Mn

  10. 10

    Investment in R&D: INR 5,352 Mn

Management Comments

M

Mr. Nilesh Gupta

We are happy to deliver another quarter of strong growth led by our highest ever quarterly sales in the US and double-digit growth in India and all other regions. We are on track to deliver a strong close to FY26.

Informational and educational content only. Not investment advice.